BR112017022478A2 - composição farmacêutica de liberação sustentada que contém rivastigmina - Google Patents

composição farmacêutica de liberação sustentada que contém rivastigmina

Info

Publication number
BR112017022478A2
BR112017022478A2 BR112017022478-0A BR112017022478A BR112017022478A2 BR 112017022478 A2 BR112017022478 A2 BR 112017022478A2 BR 112017022478 A BR112017022478 A BR 112017022478A BR 112017022478 A2 BR112017022478 A2 BR 112017022478A2
Authority
BR
Brazil
Prior art keywords
sustained release
pharmaceutical composition
composition containing
containing rivastigmine
release composition
Prior art date
Application number
BR112017022478-0A
Other languages
English (en)
Other versions
BR112017022478B1 (pt
Inventor
Geun Park Sang
Gyeong Shin Hye
Woo Bae Jeong
Ju Choi Hyun
Original Assignee
Navipharm Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navipharm Co., Ltd. filed Critical Navipharm Co., Ltd.
Publication of BR112017022478A2 publication Critical patent/BR112017022478A2/pt
Publication of BR112017022478B1 publication Critical patent/BR112017022478B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se a uma composição farmacêutica de liberação sustentada que contém rivastigmina e, mais especificamente, a uma composição farmacêutica de liberação sustentada que contém rivastigmina em que a composição é um preparado de liberação sustentada que contém uma formulação de liberação retardada dependente do ph, e em que, por meio do controle da liberação da composição farmacêutica a ser minimizada no estômago no estágio inicial da administração, a composição farmacêutica pode reduzir a concentração máxima de sangue (cmax) em comparação com os produtos existentes, enquanto atinge uma concentração eficaz do sangue, desse modo reduzindo os efeitos colaterais, e mantendo a seguir a concentração eficaz do sangue através da liberação sustentadas dos ingredientes principais. como resultado, a composição farmacêutica de acordo com a presente invenção exibe o mesmo efeito que na dosagem duas vezes ao dia existente através somente da dosagem uma vez ao dia, e pode aumentar a eficiência do tratamento dos pacientes através da melhoria na conveniência de administração dos pacientes.
BR112017022478-0A 2015-04-27 2016-04-27 Composição farmacêutica de liberação sustentada que contém rivastigmina BR112017022478B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020150058759A KR101990951B1 (ko) 2015-04-27 2015-04-27 리바스티그민 함유 서방출 의약조성물
KR10-2015-0058759 2015-04-27
PCT/KR2016/004380 WO2016175546A2 (ko) 2015-04-27 2016-04-27 리바스티그민 함유 서방출 의약조성물

Publications (2)

Publication Number Publication Date
BR112017022478A2 true BR112017022478A2 (pt) 2018-07-10
BR112017022478B1 BR112017022478B1 (pt) 2023-11-21

Family

ID=57199589

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017022478-0A BR112017022478B1 (pt) 2015-04-27 2016-04-27 Composição farmacêutica de liberação sustentada que contém rivastigmina

Country Status (21)

Country Link
US (1) US10835497B2 (pt)
EP (1) EP3290023B1 (pt)
JP (1) JP6787928B2 (pt)
KR (1) KR101990951B1 (pt)
CN (1) CN107530290B (pt)
AU (1) AU2016255302B2 (pt)
BR (1) BR112017022478B1 (pt)
CA (1) CA2984235C (pt)
CY (1) CY1124339T1 (pt)
DK (1) DK3290023T3 (pt)
ES (1) ES2860694T3 (pt)
HR (1) HRP20210434T1 (pt)
HU (1) HUE053816T2 (pt)
LT (1) LT3290023T (pt)
MX (1) MX2017013481A (pt)
PL (1) PL3290023T3 (pt)
PT (1) PT3290023T (pt)
RS (1) RS61548B1 (pt)
RU (1) RU2727721C2 (pt)
SI (1) SI3290023T1 (pt)
WO (1) WO2016175546A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102209420B1 (ko) * 2019-03-08 2021-01-29 에이치엘비제약 주식회사 리바스티그민의 일정한(0-차) 방출형 경구용 서방성 정제 조성물
CN112546037A (zh) * 2020-12-08 2021-03-26 苏州大学 卡巴拉汀在制备抗辐射药中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1121104E (pt) * 1998-10-01 2005-05-31 Novartis Ag Novas formulacoes orais de libertacao controlada
CA2380333A1 (en) * 1999-08-26 2001-03-01 Christian Andina Pharmaceutical formulations
JP2003507416A (ja) * 1999-08-26 2003-02-25 エラン コーポレイション ピーエルスィー 医薬製剤
GB9923045D0 (en) 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US20050163847A1 (en) * 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
AU2005320547B2 (en) * 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
RU2390354C2 (ru) * 2004-12-27 2010-05-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Препарат матричного типа с замедленным высвобождением, содержащий основное лекарственное средство или его соль, и способ его получения
MX2007012220A (es) * 2005-04-06 2007-12-06 Mallinckrodt Inc Formulacion farmaceutica de liberacion por pulsos a base de matriz.
WO2007064675A2 (en) * 2005-11-29 2007-06-07 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
JP5052602B2 (ja) * 2006-05-12 2012-10-17 シャイア エルエルシー 制御用量薬物送達システム
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
WO2011049309A2 (ko) 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
WO2011123496A1 (en) 2010-03-31 2011-10-06 Supernus Pharmaceuticals, Inc. Formulations of mazindol
CN108653226A (zh) * 2013-03-15 2018-10-16 韩国联合制药株式会社 提供药理及临床效应的莫沙必利每日单次施用缓释制剂

Also Published As

Publication number Publication date
SI3290023T1 (sl) 2021-08-31
ES2860694T3 (es) 2021-10-05
KR101990951B1 (ko) 2019-06-20
RS61548B1 (sr) 2021-04-29
EP3290023A4 (en) 2018-12-19
EP3290023B1 (en) 2021-02-17
HUE053816T2 (hu) 2021-07-28
JP6787928B2 (ja) 2020-11-18
CN107530290A (zh) 2018-01-02
LT3290023T (lt) 2021-03-25
EP3290023A2 (en) 2018-03-07
BR112017022478B1 (pt) 2023-11-21
KR20160127405A (ko) 2016-11-04
US10835497B2 (en) 2020-11-17
CA2984235C (en) 2023-02-21
RU2017136567A (ru) 2019-05-27
RU2017136567A3 (pt) 2019-09-19
AU2016255302A1 (en) 2017-12-07
AU2016255302B2 (en) 2021-03-04
CN107530290B (zh) 2021-04-27
PT3290023T (pt) 2021-03-24
WO2016175546A2 (ko) 2016-11-03
CY1124339T1 (el) 2022-07-22
JP2018514530A (ja) 2018-06-07
US20180125785A1 (en) 2018-05-10
RU2727721C2 (ru) 2020-07-23
HRP20210434T1 (hr) 2021-04-30
DK3290023T3 (da) 2021-04-12
PL3290023T3 (pl) 2021-08-30
MX2017013481A (es) 2018-05-17
WO2016175546A3 (ko) 2016-12-22
CA2984235A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
BR112015000136A2 (pt) fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
BR112017017888A2 (pt) derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
BR112016027469A2 (pt) composição para tratamento de diabetes que compreende conjugado de análogo de insulina de ação lenta e conjugado de peptídeo insulinotrópico de ação lenta
NI201100194A (es) Derivados de tieno [2, 3 - b] piridina como inhibidores de la replicación viral
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
EA201590836A1 (ru) Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
BR112018000242A2 (pt) composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico
JP2020530857A5 (pt)
BR112023024741A2 (pt) Composto de quinolinamina, método de preparação para o mesmo e aplicação do mesmo em produtos farmacêuticos
BR112014026442A2 (pt) composição farmacêutica
BR112017022478A2 (pt) composição farmacêutica de liberação sustentada que contém rivastigmina
BR112015023806A2 (pt) Novos regimes de dosagem de celgosivir para o tratamento de dengue
BR112012027864A2 (pt) agente de elevação do teor de colágeno na pele
BR112015009291A2 (pt) métodos para o controle da pressão arterial e redução da dispnéia na insuficiência cardíaca
BR112018016817A2 (pt) composição farmacêutica e método de tratamento da deficiência do hormônio do crescimento
BR112018016287A2 (pt) sistema de perfusão, método para administrar diretamente a um paciente em necessidade do mesmo uma dose de um fármaco antineoplásico e recipiente de perfusão
BR112018072183A2 (pt) composição farmacêutica, e, método para prevenir uma doença de pele
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/04/2016, OBSERVADAS AS CONDICOES LEGAIS